en

Albert Hofmann

Albert Hofmann (January 11, 1906 – April 29, 2008) was a Swiss scientist known best for being the first person to synthesize, ingest, and learn of the psychedelic effects of lysergic acid diethylamide (LSD). Hofmann was also the first person to isolate, synthesize, and name the principal psychedelic mushroom compounds psilocybin and psilocin. He authored more than 100 scientific articles and numerous books, including LSD: My Problem Child. In 2007 he shared first place, alongside Tim Berners-Lee, in a list of the 100 greatest living geniuses, published by The Telegraph newspaper.Hofmann was born in Baden, Switzerland, the first of four children to factory toolmaker Adolf Hofmann and his wife Elisabeth (born Elisabeth Schenk). Owing to his father's low income, Albert's godfather paid for his education. When his father became ill, Hofmann obtained a position as a commercial apprentice in concurrence with his studies. At the age of twenty, Hofmann began his chemistry degree at the University of Zürich, finishing three years later, in 1929. His main interest was the chemistry of plants and animals, and he later conducted important research on the chemical structure of the common animal substance chitin, for which he received his doctorate, with distinction, in the spring of 1929.Hofmann became an employee of the pharmaceutical-chemical department of Sandoz Laboratories (now a subsidiary of Novartis), located in Basel as a co-worker with professor Arthur Stoll, founder and director of the pharmaceutical department. He began studying the medicinal plant squill and the fungus ergot as part of a program to purify and synthesize active constituents for use as pharmaceuticals. His main contribution was to elucidate the chemical structure of the common nucleus of the Scilla glycosides (an active principal of Mediterranean Squill). While researching lysergic acid derivatives, Hofmann first synthesized LSD on November 16, 1938. The main intention of the synthesis was to obtain a respiratory and circulatory stimulant (an analeptic) with no effects on the uterus in analogy to nikethamide (which is also a diethylamide) by introducing this functional group to lysergic acid. It was set aside for five years, until April 16, 1943, when Hofmann decided to reexamine it.Hofmann, later, was to discover 4-Acetoxy-DET (4-acetoxy-N,N-diethyltryptamine), also known as ethacetin, ethylacybin, or 4-AcO-DET, a hallucinogenic tryptamine. He first synthesized 4-AcO-DET in 1958 in the Sandoz lab. Hofmann became director of the natural products department at Sandoz and continued studying hallucinogenic substances found in Mexican mushrooms and other plants used by the aboriginal people there.In 1962, he and his wife Anita Hofmann née Guanella (born Guanella, sister of Gustav Guanella, an important Swiss inventor) traveled to southern Mexico to search for the plant "Ska Maria Pastora" (Leaves of Mary the Shepherdess), later known as Salvia divinorum. He was able to obtain samples of this plant, but never succeeded in identifying its active compound, which has since been identified as the diterpenoid salvinorin A. In 1963, Hofmann attended the annual convention of the World Academy of Arts and Sciences (WAAS) in Stockholm.Hofmann died of a heart attack on April 29, 2008 and was survived by several grandchildren and great-grandchildren. He and his wife, Anita, reared four children, one of whom died at the age of 53.The Swiss Federal Institute of Technology (ETH Zurich) honored him with the title D.Sc. (honoris causa) in 1969 together with Gustav Guanella, his brother-in-law. In 1971 the Swedish Pharmaceutical Association (Sveriges Farmacevtförbund) granted him the Scheele Award, which commemorates the skills and achievements of the Swedish Pomeranian chemist and pharmacist Carl Wilhelm Scheele.

Kitaplar

Sesli kitaplar

Alıntılar

Nikolai C.alıntı yaptı2 ay önce
In addition to the unpredictability of a substance’s effects on a biological subject based on its chemical structure, there is the unpredictability of its effects on humans based on its activity in animal research.

As a result, only a very small percentage of experimental preparations that end up in clinical tests prove to have a therapeutic value for humans.
Nikolai C.alıntı yaptı2 ay önce
To quote Louis Pasteur, “In the realm of scientific observation, luck is granted only to those who are prepared.”
Nikolai C.alıntı yaptı2 ay önce
The structure of the mushroom’s active ingredient is noteworthy among other things, because it is closely related to serotonin as well as because, like lysergic acid and LSD, it incorporates an indole derivative that is substituted at position 4. In my opinion psilocybin and psilocin deserve further attention in experimental psychiatry and as prototypes for chemical modification. But psilocybin research has already produced useful information and led indirectly, as LSD did, to important new medicines.
fb2epub
Dosyalarınızı sürükleyin ve bırakın (bir kerede en fazla 5 tane)